PEAK6 Group’s TherapeuticsMD TXMD Stock Holding History

PEAK6 Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-410	Closed	-$161K	–	5613
2015 Q2	$161K	Buy	+410	New	+$145K	﹤0.01%	3929

Other funds holding TXMD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6 Group's TXMD Position: Q3 2015 in Review

PEAK6 Group sold out of TherapeuticsMD (TXMD) in Q3 2015, closing a stake of 295 shares — an estimated $116K sold.

PEAK6 Group first reported a position in TXMD in Q2 2015 and held it in 1 quarter. The position peaked at $116K in Q2 2015. 114 funds tracked by Wall St. Rank hold TXMD as of Q3 2015.

PEAK6 Group reported no remaining TherapeuticsMD position as of Q3 2015 after selling out during the quarter.
PEAK6 Group sold 295 TherapeuticsMD shares in Q3 2015, an estimated $116K.
PEAK6 Group first reported a position in TherapeuticsMD in Q2 2015 and held it in 1 quarter.
PEAK6 Group's TherapeuticsMD position peaked at $116K in Q2 2015.
114 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2015.

Based on PEAK6 Group's 13F filing for Q3 2015, filed 16 Nov 2015.